GlassScriptPhysician profile
Anthony Huynh
NPI 1497766364
$16,338.57
in general payments reported to CMS, 2019-2025
31 companies · $5,165 in 2025
The $5,165 reported for 2025 was more than what 90% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $217 · 2021: $1,384 · 2022: $3,834 · 2023: $1,815 · 2024: $2,971 · 2025: $5,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,111 · Honoraria: $2,750 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,110.53 |
| Honoraria | $2,750.00 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lnhc, INC | $2,884.26 | 2025 | Zelsuvmi |
| Galderma Laboratories, L.P. | $2,293.50 | 2019-2025 | Aklief, Nemluvio |
| Genzyme Corporation | $1,515.88 | 2019-2025 | |
| Abbvie INC. | $1,313.97 | 2019-2025 | |
| Amgen INC. | $1,273.77 | 2022-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $1,223.51 | 2023-2025 | Zoryve |
| Incyte Corporation | $889.14 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $779.47 | 2021-2025 | Ilumya, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $686.21 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $566.29 | 2023-2024 | Vtama |
| Lilly USA, LLC | $427.40 | 2020-2022 | |
| Leo Pharma INC. | $328.56 | 2023-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $320.92 | 2021-2025 | Libtayo, Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $300.53 | 2019-2021 | |
| Ucb, INC. | $295.49 | 2020-2025 | Bimzelx |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $235.63 | 2021-2024 | Tremfya |
| Pfizer INC. | $228.77 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $160.01 | 2019-2020 | |
| Glaxosmithkline, LLC. | $125.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $75.68 | 2024-2025 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.78 | 2023-2024 | Spevigo, Cyltezo |
| Myriad Genetic Laboratories, INC. | $59.09 | 2023 | Myrisk |
| Organon LLC | $53.44 | 2025 | Vtama |
| Kyowa Kirin, INC. | $43.16 | 2020-2021 | |
| Biofrontera INC. | $39.15 | 2019-2021 | |
| Mimedx Group, INC. | $29.32 | 2024 | |
| Sanofi-Aventis U.S. LLC | $29.29 | 2021 | |
| Smith+Nephew, INC. | $28.62 | 2021-2022 | |
| Dermira, INC. | $27.54 | 2019 | |
| Strata Skin Sciences, INC. | $21.02 | 2023 | Xtrac |
| Prugen, INC. Pharmaceuticals | $19.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Huynh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.